BV3A Stock Overview
Develops, manufactures, and commercializes life-saving vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BV3A from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Bavarian Nordic A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 8.60 |
| 52 Week High | DKK 14.80 |
| 52 Week Low | DKK 6.15 |
| Beta | 1.59 |
| 1 Month Change | 8.86% |
| 3 Month Change | -19.63% |
| 1 Year Change | 16.22% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -12.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| BV3A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.8% | -1.2% | -1.4% |
| 1Y | 16.2% | -13.2% | 8.0% |
Return vs Industry: BV3A exceeded the German Biotechs industry which returned -12.8% over the past year.
Return vs Market: BV3A exceeded the German Market which returned 8.1% over the past year.
Price Volatility
| BV3A volatility | |
|---|---|
| BV3A Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BV3A has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BV3A's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,609 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
Bavarian Nordic A/S Fundamentals Summary
| BV3A fundamental statistics | |
|---|---|
| Market cap | €2.09b |
| Earnings (TTM) | €149.93m |
| Revenue (TTM) | €813.58m |
14.0x
P/E Ratio2.6x
P/S RatioIs BV3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BV3A income statement (TTM) | |
|---|---|
| Revenue | DKK 6.07b |
| Cost of Revenue | DKK 2.33b |
| Gross Profit | DKK 3.74b |
| Other Expenses | DKK 2.62b |
| Earnings | DKK 1.12b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 05, 2025
| Earnings per share (EPS) | 14.24 |
| Gross Margin | 61.57% |
| Net Profit Margin | 18.43% |
| Debt/Equity Ratio | 0.1% |
How did BV3A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 12:02 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bavarian Nordic A/S is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Ankersen | ABG Sundal Collier |
| Jacob Lademann | Carnegie Investment Bank AB |
| Peter Verdult | Citigroup Inc |